Mechanistic insights into how Canagliflozin aids in control of body weight, energy homeostasis and TIIDM:  Canagliflozin (brand name: Invokana, Sulisent, Prominad, others), a  drug used in the treatment of type II diabetes, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 5/May/2019, 6.39 am

All sweets are not bad, some are good too: Have copious amounts of Isomaltulose for safeguarding your heart against cardiac dysfunction: Isomaltulose/Palatinose, a disaccharide consisting of glucose and fructose found in honey and sugar cane extract, decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 5/May/2019, 6.23 am
May 5, 2019
Mechanistic insights into how Liraglutide may aid in the treatment of Diabetes: Liraglutide (brand name: Victoza, Saxenda, others), an acylated glucagon-like peptide-1 (GLP-1) agonist used in the treatment of Type II diabetes, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 5/May/2018, 7.09 am
May 5, 2019
Show all

Introduction: What they say

A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.” This research paper was published, in the 29 March 2012 issue of the journal “Nature” [One of the best research journals in Science with an I.F of 43 plus], by Prof.Burris TP, Solt LA and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Mechanistic insights into how Canagliflozin aids in control of body weight, energy homeostasis and TIIDM:  Canagliflozin (brand name: Invokana, Sulisent, Prominad, others), a  drug used in the treatment of type II diabetes, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) more than half a billion adults are obese worldwide ; (2) obesity is more prevalent in western countries than in asian countries; (3) obesity results in deregulated blood pressure, cholesterol, triglycerides and insulin sensitivity; and the risks of coronary heart disease, ischemic stroke and TII diabetes mellitus(TIIDM) increase ; (4) more than 422 million people worldwide are affected by Diabetes mellitus (DM); (5) Diabetes is going to be one of the top 10 causes of death by 2030; (6) the life-long painful injection/drug treatment is required to treat DM; and  (7) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, obesity-associated diseases, including diabetes.


What is known?

Prof.Burris’s research team has recently shown that administration of REV-ERB ligands:(1) regulates circadian behaviour and the circadian pattern of core clock gene;(2) alters the circadian pattern of expression of metabolic genes in liver, skeletal muscle and adipose tissue; (3) increases energy expenditure; (4) inhibits lipid accumulation; (4) decreases obesity; (5) improves dyslipidemia; and (6) reduces hyperglycaemia, suggesting that increasing the expression of REV-ERB may promote weight loss, augment insulin sensitivity, improve dyslipidemia and alleviate Obesity-associated TIIDM.


From Research findings to Therapeutic opportunity:

I had suggested earlier ( on 15/November/2018 at 10.02 pm and in other studies) that Canagliflozin  may protect against myocardial dysfunction (https://genomediscovery.org/2018/11/the-known-anti-hyperglycemic-agent-empagliflozin-empa-may-safeguard-your-heart-against-cardiac-dysfunction-empagliflozin-empa-a-drug-used-in-the-treatment-of-tiidm/; &

https://genomediscovery.org/2019/04/molecular-therapy-for-cardiac-dysfunction-canagliflozin-trade-name-invokana-a-medication-used-to-hyperglycemia-decreases-mir-29-expression-activates-wnt-signaling-and-its-compon/).

Evidently, a very recent study from the the Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, the George Institute for Global Health, University of New South Wales Sydney, the Royal North Shore Hospital and others shows that “Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.” This study was published, in the 14 April 2019 issue of of the prestigious journal N Engl J Med. (NEJM) (Impact factor: 79.258+) ,  by Prof. Mahaffey KW, Perkovic V, Brenner BM and others. In concordance with what I stated earlier, this study suggests that Canagliflozin lowers the risk of heart failure.  However, the mechanism of action of this drug is not known yet. 

This study substantiates their claim by providing a detailed mechanistic insights into how Canagliflozin  may aid in attenuating insulin resistance and in the treatment of weight loss and obesity-associated TIIDM.

Canagliflozin, by increasing the expression of its target gene, it may increase the expression of REV-ERB (Fig.1). Thereby, it may: (1) normalize circadian pattern of metabolic genes; (2) augment energy expenditure; (3) inhibit lipid accumulation; (4) promote weight loss; (5) ameliorate dyslipidemia; and (6) inhibit hyperglycemia (Fig.1).

Figure 1. Mechanistic insights into how Canagliflozin attenuates metabolic disease and obesity-associated TIIDM.  Canagliflozin, by up regulating the expression of its target gene, it may increase REV-ERB. And thereby it may attenuate metabolic disease and obesity-associated TIIDM.

Figure 2.  Canagliflozin promotes weight loss and attenuates metabolic disease through induction of Rev-ERB.

Thus, pharmacological formulations encompassing ” Canagliflozin or its analogues , either alone or in combination with other drugs” may be used:(i) as a weight-loss medication; (ii) to treat Obesity-associated TIIDM; (iii) to treat sleep disorders (Fig.2).


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does  Canagliflozin increase the expression of REV-ERB?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L.,  Mechanistic insights into how Canagliflozin aids in control of body weight, energy homeostasis and TIIDM:  Canagliflozin (brand name: Invokana, Sulisent, Prominad, others), a  drug used in the treatment of type II diabetes, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 5/May/2019, 6.39 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

 

 

 

Comments are closed.